Hepatobiliary manifestations of inflammatory bowel disease

Andres J. Yarur, Frank Czul, Cynthia Levy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Patients with inflammatory bowel diseases (IBDs) may present with several hepatic abnormalities. Some of these liver diseases are benign and only require observation, whereas others may cause liver failure and require liver transplantation. The aim of this review was to present and summarize the latest evidence on the most common liver diseases seen in patients with IBD. These manifestations can be divided in to 3 groups: those that are seen in association with IBD, those that are due to metabolic and physiologic changes induced by the IBD and those that are secondary to the drugs used in the treatment of IBD. Primary sclerosing cholangitis is one of the most common hepatobiliary manifestations of IBD that is more prevalent in patients with ulcerative colitis. There is no approved medical treatment for primary sclerosing cholangitis and about 50% of patients will require liver transplantation within 10 to 15 years from the time of diagnosis. Among the drugs that are commonly used in the treatment of IBD, thiopurines and methotrexate impose the higher risk of hepatotoxicity. In most cases, dose adjustment and avoidance of hepatotoxins will normalize the liver tests and discontinuation of the drug is required in a minority of cases. Reactivation of hepatitis B virus during immunosuppressive therapy is a major concern and adequate screening and vaccination is warranted. The approach to a patient with IBD who presents with abnormal liver chemistries can be challenging not only because 2 or more conditions can co-exist but also because management must be individualized.

Original languageEnglish (US)
Pages (from-to)1655-1667
Number of pages13
JournalInflammatory Bowel Diseases
Volume20
Issue number9
DOIs
StatePublished - Dec 1 2014

Fingerprint

Inflammatory Bowel Diseases
Sclerosing Cholangitis
Liver Transplantation
Liver Diseases
Liver
Pharmaceutical Preparations
Liver Failure
Therapeutics
Immunosuppressive Agents
Ulcerative Colitis
Hepatitis B virus
Methotrexate
Vaccination
Observation

Keywords

  • Azathioprine
  • Crohn's disease
  • Drug-induced liver disease
  • Hepatitis B
  • Inflammatory bowel diseases
  • Infliximab
  • Liver diseases
  • Mercaptopurine
  • Methotrexate
  • Primary sclerosing cholangitis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Hepatobiliary manifestations of inflammatory bowel disease. / Yarur, Andres J.; Czul, Frank; Levy, Cynthia.

In: Inflammatory Bowel Diseases, Vol. 20, No. 9, 01.12.2014, p. 1655-1667.

Research output: Contribution to journalArticle

Yarur, Andres J. ; Czul, Frank ; Levy, Cynthia. / Hepatobiliary manifestations of inflammatory bowel disease. In: Inflammatory Bowel Diseases. 2014 ; Vol. 20, No. 9. pp. 1655-1667.
@article{f3713b79fa444b3f99cb8aafcdb6cb50,
title = "Hepatobiliary manifestations of inflammatory bowel disease",
abstract = "Patients with inflammatory bowel diseases (IBDs) may present with several hepatic abnormalities. Some of these liver diseases are benign and only require observation, whereas others may cause liver failure and require liver transplantation. The aim of this review was to present and summarize the latest evidence on the most common liver diseases seen in patients with IBD. These manifestations can be divided in to 3 groups: those that are seen in association with IBD, those that are due to metabolic and physiologic changes induced by the IBD and those that are secondary to the drugs used in the treatment of IBD. Primary sclerosing cholangitis is one of the most common hepatobiliary manifestations of IBD that is more prevalent in patients with ulcerative colitis. There is no approved medical treatment for primary sclerosing cholangitis and about 50{\%} of patients will require liver transplantation within 10 to 15 years from the time of diagnosis. Among the drugs that are commonly used in the treatment of IBD, thiopurines and methotrexate impose the higher risk of hepatotoxicity. In most cases, dose adjustment and avoidance of hepatotoxins will normalize the liver tests and discontinuation of the drug is required in a minority of cases. Reactivation of hepatitis B virus during immunosuppressive therapy is a major concern and adequate screening and vaccination is warranted. The approach to a patient with IBD who presents with abnormal liver chemistries can be challenging not only because 2 or more conditions can co-exist but also because management must be individualized.",
keywords = "Azathioprine, Crohn's disease, Drug-induced liver disease, Hepatitis B, Inflammatory bowel diseases, Infliximab, Liver diseases, Mercaptopurine, Methotrexate, Primary sclerosing cholangitis, Ulcerative colitis",
author = "Yarur, {Andres J.} and Frank Czul and Cynthia Levy",
year = "2014",
month = "12",
day = "1",
doi = "10.1097/MIB.0000000000000065",
language = "English (US)",
volume = "20",
pages = "1655--1667",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Hepatobiliary manifestations of inflammatory bowel disease

AU - Yarur, Andres J.

AU - Czul, Frank

AU - Levy, Cynthia

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Patients with inflammatory bowel diseases (IBDs) may present with several hepatic abnormalities. Some of these liver diseases are benign and only require observation, whereas others may cause liver failure and require liver transplantation. The aim of this review was to present and summarize the latest evidence on the most common liver diseases seen in patients with IBD. These manifestations can be divided in to 3 groups: those that are seen in association with IBD, those that are due to metabolic and physiologic changes induced by the IBD and those that are secondary to the drugs used in the treatment of IBD. Primary sclerosing cholangitis is one of the most common hepatobiliary manifestations of IBD that is more prevalent in patients with ulcerative colitis. There is no approved medical treatment for primary sclerosing cholangitis and about 50% of patients will require liver transplantation within 10 to 15 years from the time of diagnosis. Among the drugs that are commonly used in the treatment of IBD, thiopurines and methotrexate impose the higher risk of hepatotoxicity. In most cases, dose adjustment and avoidance of hepatotoxins will normalize the liver tests and discontinuation of the drug is required in a minority of cases. Reactivation of hepatitis B virus during immunosuppressive therapy is a major concern and adequate screening and vaccination is warranted. The approach to a patient with IBD who presents with abnormal liver chemistries can be challenging not only because 2 or more conditions can co-exist but also because management must be individualized.

AB - Patients with inflammatory bowel diseases (IBDs) may present with several hepatic abnormalities. Some of these liver diseases are benign and only require observation, whereas others may cause liver failure and require liver transplantation. The aim of this review was to present and summarize the latest evidence on the most common liver diseases seen in patients with IBD. These manifestations can be divided in to 3 groups: those that are seen in association with IBD, those that are due to metabolic and physiologic changes induced by the IBD and those that are secondary to the drugs used in the treatment of IBD. Primary sclerosing cholangitis is one of the most common hepatobiliary manifestations of IBD that is more prevalent in patients with ulcerative colitis. There is no approved medical treatment for primary sclerosing cholangitis and about 50% of patients will require liver transplantation within 10 to 15 years from the time of diagnosis. Among the drugs that are commonly used in the treatment of IBD, thiopurines and methotrexate impose the higher risk of hepatotoxicity. In most cases, dose adjustment and avoidance of hepatotoxins will normalize the liver tests and discontinuation of the drug is required in a minority of cases. Reactivation of hepatitis B virus during immunosuppressive therapy is a major concern and adequate screening and vaccination is warranted. The approach to a patient with IBD who presents with abnormal liver chemistries can be challenging not only because 2 or more conditions can co-exist but also because management must be individualized.

KW - Azathioprine

KW - Crohn's disease

KW - Drug-induced liver disease

KW - Hepatitis B

KW - Inflammatory bowel diseases

KW - Infliximab

KW - Liver diseases

KW - Mercaptopurine

KW - Methotrexate

KW - Primary sclerosing cholangitis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84925865005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925865005&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000065

DO - 10.1097/MIB.0000000000000065

M3 - Article

VL - 20

SP - 1655

EP - 1667

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -